Open AccessIrinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis
Author(s) -
Zili Liu,
Bin Wang,
Jizhu Liu,
Weiwei Liu
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.199387
Subject(s) - medicine , irinotecan , regimen , neutropenia , etoposide , cochrane library , gastroenterology , relative risk , randomized controlled trial , oncology , confidence interval , chemotherapy , cancer , colorectal cancer
To systematically review the effect and safety of irinotecan plus cisplatin (IP) compared with etoposide plus cisplatin (EP) in patients with previously untreated extensive-stage small cell lung cancer (E-SCLC).